Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
or

Orchid Island Capital Inc (ORC)

Orchid Island Capital Inc (ORC)
6.00 -0.46 (-7.12%) 11:51 ET [NYSE]
5.99 x 230 6.00 x 200
Realtime by (Cboe BZX)
5.99 x 230 6.00 x 200
Realtime 6.38 -0.08 (-1.24%) 09:30 ET
Quote Overview for Thu, Apr 10th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
5.94
Day High
6.38
Open 6.37
Previous Close 6.46 6.46
Volume 3,050,334 3,050,334
Avg Vol 4,254,546 4,254,546
Stochastic %K 16.14% 16.14%
Weighted Alpha -35.48 -35.48
5-Day Change -1.09 (-15.29%) -1.09 (-15.29%)
52-Week Range 5.68 - 9.01 5.68 - 9.01
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 602,679
  • Shares Outstanding, K 93,294
  • Annual Sales, $ 241,580 K
  • Annual Income, $ 37,660 K
  • EBIT $ 274 M
  • EBITDA $ 274 M
  • 60-Month Beta 1.68
  • Price/Sales 2.38
  • Price/Cash Flow N/A
  • Price/Book 0.76

Options Overview Details

View History
  • Implied Volatility 64.01% ( +5.49%)
  • Historical Volatility 38.64%
  • IV Percentile 93%
  • IV Rank 47.68%
  • IV High 111.72% on 09/18/24
  • IV Low 20.52% on 05/20/24
  • Put/Call Vol Ratio 2.50
  • Today's Volume 49
  • Volume Avg (30-Day) 212
  • Put/Call OI Ratio 0.51
  • Today's Open Interest 5,817
  • Open Int (30-Day) 3,907

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.02
  • Number of Estimates 1
  • High Estimate 0.02
  • Low Estimate 0.02
  • Prior Year -0.12
  • Growth Rate Est. (year over year) +116.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.68 +6.68%
on 04/09/25
Period Open: 8.36
8.44 -28.16%
on 03/19/25
-2.29 (-27.45%)
since 03/10/25
3-Month
5.68 +6.68%
on 04/09/25
Period Open: 7.75
9.01 -32.65%
on 02/21/25
-1.68 (-21.74%)
since 01/10/25
52-Week
5.68 +6.68%
on 04/09/25
Period Open: 8.27
9.01 -32.65%
on 02/21/25
-2.21 (-26.66%)
since 04/10/24

Most Recent Stories

More News
Orchid Island Capital Announces Estimated First Quarter 2025 Results, April 2025 Monthly Dividend and March 31, 2025 RMBS Portfolio Characteristics

ORC : 6.00 (-7.12%)
Bimini Capital Management to Announce First Quarter 2025 Results

ORC : 6.00 (-7.12%)
BMNM : 0.9700 (-13.78%)
Orchid Island Capital to Announce First Quarter 2025 Results

ORC : 6.00 (-7.12%)
Orchid Island Capital Announces March 2025 Monthly Dividend and February 28, 2025 RMBS Portfolio Characteristics

ORC : 6.00 (-7.12%)
12% Dividend Yield: Bargains or Traps?

A brief article by Colorado Wealth Management Fund

ORC : 6.00 (-7.12%)
ARR : 13.79 (-8.37%)
EFC : 11.50 (-4.96%)
AGNC : 8.10 (-9.09%)
MFA : 8.31 (-9.67%)
OCSL : 13.39 (-3.67%)
TPVG : 5.93 (-4.51%)
ARCC : 19.86 (-4.79%)
DX : 11.16 (-6.38%)
NYMT : 5.22 (-7.77%)
RITM : 9.52 (-8.11%)
NLY : 17.22 (-8.50%)
Orchid Island Capital Announces February 2025 Monthly Dividend and January 31, 2025 RMBS Portfolio Characteristics

ORC : 6.00 (-7.12%)
Orchid Island: Q4 Earnings Snapshot

Orchid Island: Q4 Earnings Snapshot

ORC : 6.00 (-7.12%)
Orchid Island Capital Announces Fourth Quarter 2024 Results

ORC : 6.00 (-7.12%)
Orchid Island Capital To Announce Fourth Quarter 2024 Results

ORC : 6.00 (-7.12%)
Orchid Island Capital Announces Estimated Fourth Quarter 2024 Results January 2025 Monthly Dividend and December 31, 2024 RMBS Portfolio Characteristics

ORC : 6.00 (-7.12%)
AnaptysBio Discontinues ANB032 Development After Phase 2a Trial Fails to Meet Efficacy Endpoints

AnaptysBio halts ANB032 investment after ineffective trial results; focuses on other assets, with cash runway through 2027.Quiver AI SummaryAnaptysBio, Inc. announced that its investigational drug ANB032,...

ANAB : 15.97 (-5.50%)
Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis

ANAB : 15.97 (-5.50%)
Anaptys Announces Participation in November and December Investor Conferences

ANAB : 15.97 (-5.50%)
Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update

ANAB : 15.97 (-5.50%)
Why AnaptysBio Was Such a Healthy Stock This Week

The company's immediate future looks promising, as it has a drug that should get a clinical readout within months and a deep-pocketed pharmaceutical peer as an investor.

ANAB : 15.97 (-5.50%)
Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week

A powerfully bullish new analyst take on the company helped it rally on the market.

WFC : 63.03 (-4.98%)
LLY : 704.98 (-6.47%)
ANAB : 15.97 (-5.50%)
Argenx's 28% Surge & Promising Product Propel Investor Confidence

Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.

ARGX : 542.28 (-3.87%)
ABBV : 168.00 (-6.58%)
ABCL : 2.00 (-8.06%)
ALNY : 221.67 (-8.88%)
AMGN : 274.97 (-5.54%)
ANAB : 15.97 (-5.50%)
AZN : 64.11 (-3.97%)
BMY : 50.18 (-6.62%)
INCY : 55.08 (-6.42%)
REGN : 542.98 (-5.85%)
VIE : 53.01 (unch)
AnaptysBio Announces Second Quarter 2022 Financial Results and Provides Pipeline Update

Top-line data from the ongoing imsidolimab (anti-IL-36R Ab) HARP Phase 2 trial in moderate-to-severe hidradenitis suppurativa is anticipated in Q3...

ANAB : 15.97 (-5.50%)
AnaptysBio to Participate at the 2022 Wedbush PacGrow Healthcare Virtual Conference

SAN DIEGO, Aug. 05, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative...

ANAB : 15.97 (-5.50%)
AnaptysBio to Participate at the 2022 Jefferies Healthcare Conference

SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibodies...

ANAB : 15.97 (-5.50%)
AnaptysBio Discontinues ANB032 Development After Phase 2a Trial Fails to Meet Efficacy Endpoints

AnaptysBio halts ANB032 investment after ineffective trial results; focuses on other assets, with cash runway through 2027.Quiver AI SummaryAnaptysBio, Inc. announced that its investigational drug ANB032,...

ANAB : 15.97 (-5.50%)
Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis

ANAB : 15.97 (-5.50%)
Anaptys Announces Participation in November and December Investor Conferences

ANAB : 15.97 (-5.50%)
Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update

ANAB : 15.97 (-5.50%)
Why AnaptysBio Was Such a Healthy Stock This Week

The company's immediate future looks promising, as it has a drug that should get a clinical readout within months and a deep-pocketed pharmaceutical peer as an investor.

ANAB : 15.97 (-5.50%)
Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week

A powerfully bullish new analyst take on the company helped it rally on the market.

WFC : 63.03 (-4.98%)
LLY : 704.98 (-6.47%)
ANAB : 15.97 (-5.50%)
Argenx's 28% Surge & Promising Product Propel Investor Confidence

Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.

ARGX : 542.28 (-3.87%)
ABBV : 168.00 (-6.58%)
ABCL : 2.00 (-8.06%)
ALNY : 221.67 (-8.88%)
AMGN : 274.97 (-5.54%)
ANAB : 15.97 (-5.50%)
AZN : 64.11 (-3.97%)
BMY : 50.18 (-6.62%)
INCY : 55.08 (-6.42%)
REGN : 542.98 (-5.85%)
VIE : 53.01 (unch)
AnaptysBio Announces Second Quarter 2022 Financial Results and Provides Pipeline Update

Top-line data from the ongoing imsidolimab (anti-IL-36R Ab) HARP Phase 2 trial in moderate-to-severe hidradenitis suppurativa is anticipated in Q3...

ANAB : 15.97 (-5.50%)
AnaptysBio to Participate at the 2022 Wedbush PacGrow Healthcare Virtual Conference

SAN DIEGO, Aug. 05, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative...

ANAB : 15.97 (-5.50%)
AnaptysBio to Participate at the 2022 Jefferies Healthcare Conference

SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibodies...

ANAB : 15.97 (-5.50%)

Business Summary

Orchid Island Capital, Inc. is a specialty finance company that invests in residential mortgage-backed securities the principal and interest payments of which are guaranteed by a U.S. Government agency or a U.S. Government-sponsored entity. The Company intends to qualify and will elect to be taxed as...

See More

Key Turning Points

3rd Resistance Point 7.54
2nd Resistance Point 7.01
1st Resistance Point 6.74
Last Price 6.00
1st Support Level 5.93
2nd Support Level 5.41
3rd Support Level 5.13

See More

52-Week High 9.01
Fibonacci 61.8% 7.74
Fibonacci 50% 7.35
Fibonacci 38.2% 6.95
Last Price 6.00
52-Week Low 5.68

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar